Ramsey R. Hachem
( out of 13 reviews )

Ramsey R. Hachem, MD

Languages spoken: English

Clinical Locations

Primary Location

University of Utah Hospital

Pulmonary, Clinic 3
50 N Medical Dr
Salt Lake City , UT 84132
Get Directions

University of Utah Hospital

Medical Intensive Care Unit
50 N Medical Dr
Salt Lake City , UT 84132
801-581-2121
Get Directions

Ramsey Hachem, MD is an experienced Pulmonary and Critical Care physician who is board certified in Pulmonary Medicine and Critical Care Medicine. His clinical focus is lung transplantation, and he cares for people who are being considered for transplantation or have had a lung transplant. He has an active research program dedicated to understanding and managing rejection after lung transplantation.

Specialties

Board Certification

American Board of Internal Medicine (Sub: Pulmonary Disease)
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Critical Care Medicine)

Patient Rating

4.7 /5
( out of 13 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.

2025-06-27
UNIVERSITY HOSPITAL

I just filled the whole U Of U team. Transplant team has been very good

2025-05-14
UNIVERSITY HOSPITAL

Seem like a very nice person, it was nice to meet him

2025-03-12
UNIVERSITY HOSPITAL

He seems very knowledgeable in his field but he seems to be in such a hurry to end my appointment and move on to the next.

2025-03-01
UNIVERSITY HOSPITAL

Dr. Hachem is kind and takes the time to discuss medical issues and takes action.

2024-11-21
UH HOSPITALS AND CLINICS

Very professional.

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

Ramsey Hachem, MD is an experienced Pulmonary and Critical Care physician who is board certified in Pulmonary Medicine and Critical Care Medicine. His clinical focus is lung transplantation, and he cares for people who are being considered for transplantation or have had a lung transplant. He has an active research program dedicated to understanding and managing rejection after lung transplantation.

Board Certification and Academic Information

Academic Departments Internal Medicine -Professor
Academic Divisions Public Health
Board Certification
American Board of Internal Medicine (Sub: Pulmonary Disease)
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Critical Care Medicine)

Education history

Undergraduate Chemistry - Southern Methodist University B.A.
Professional Medical Medicine - University of Texas Southwestern Medical Center Medical School M.D.
Internship Internal Medicine - University of Texas Southwestern Medical Center Intern/Resident
Fellowship Pulmonary and Critical Care Medicine - Washington University School of Medicine Fellow

Selected Publications

Journal Article

  1. Hachem RR, Chakinala MM, Yusen RD, Lynch JP, Aloush AA, Patterson GA, Trulock EP (2004). The predictive value of bronchiolitis obliterans syndrome stage 0-p. Am J Respir Crit Care Med, 169(4), 468-72.
  2. Hachem RR, Chakinala MM, Yusen RD, Lynch JP, Aloush AA, Patterson GA, Trulock EP (2004). Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome. Transplantation, 77(3), 431-7.
  3. Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA, Schuster DP, Mohanakumar T, Trulock EP, Walter MJ (2004). Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med, 170(2), 181-7.
  4. Hachem RR, Chakinala MM, Yusen RD, Lynch JP, Aloush AA, Patterson GA, Trulock EP (2005). A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation. J Heart Lung Transplant, 24(9), 1320-6.
  5. Arcasoy SM, Fisher A, Hachem RR, Scavuzzo M, Ware LB, ISHLT Working Group on Primary Lung Graft Dysfunction (2005). Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part V: predictors and outcomes. J Heart Lung Transplant, 24(10), 1483-8.
  6. Hachem RR, Khalifah AP, Chakinala MM, Yusen RD, Aloush AA, Mohanakumar T, Patterson GA, Trulock EP, Walter MJ (2005). The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation, 80(10), 1406-13.
  7. Khalifah AP, Hachem RR, Chakinala MM, Yusen RD, Aloush A, Patterson GA, Mohanakumar T, Trulock EP, Walter MJ (2005). Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant, 5(8), 2022-30.
  8. Hachem RR, Yusen RD, Chakinala MM, Aloush AA, Patterson GA, Trulock EP (2006). Thrombotic microangiopathy after lung transplantation. Transplantation, 81(1), 57-63.
  9. Mikols CL, Yan L, Norris JY, Russell TD, Khalifah AP, Hachem RR, Chakinala MM, Yusen RD, Castro M, Kuo E, Patterson GA, Mohanakumar T, Trulock EP, Walter MJ (2006). IL-12 p80 is an innate epithelial cell effector that mediates chronic allograft dysfunction. Am J Respir Crit Care Med, 174(4), 461-70.
  10. Daud SA, Yusen RD, Meyers BF, Chakinala MM, Walter MJ, Aloush AA, Patterson GA, Trulock EP, Hachem RR (2007). Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med, 175(5), 507-13.
  11. Hachem RR, Yusen RD, Chakinala MM, Meyers BF, Lynch JP, Aloush AA, Patterson GA, Trulock EP (2007). A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant, 26(10), 1012-8.
  12. Hachem RR, Edwards LB, Yusen RD, Chakinala MM, Alexander Patterson G, Trulock EP (2008). The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry. Clin Transplant, 22(5), 603-8.
  13. Huang HJ, Yusen RD, Meyers BF, Walter MJ, Mohanakumar T, Patterson GA, Trulock EP, Hachem RR (2008). Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome. Am J Transplant, 8(11), 2454-62.
  14. Bharat A, Kuo E, Steward N, Aloush A, Hachem R, Trulock EP, Patterson GA, Meyers BF, Mohanakumar T (2008). Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg, 86(1), 189-95; discussion 196-7.
  15. Witt CA, Gaut JP, Yusen RD, Byers DE, Iuppa JA, Bennett Bain K, Alexander Patterson G, Mohanakumar T, Trulock EP, Hachem RR (2013). Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant, 32(10), 1034-40.
  16. Chakinala MM, Ritter J, Gage BF, Aloush AA, Hachem RH, Lynch JP, Patterson GA, Trulock EP (2005). Reliability for grading acute rejection and airway inflammation after lung transplantation. J Heart Lung Transplant, 24(6), 652-7.
  17. Morrell MR, Patterson GA, Trulock EP, Hachem RR (2009). Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant, 28(1), 96-100.
  18. Agapov E, Battaile JT, Tidwell R, Hachem R, Patterson GA, Pierce RA, Atkinson JJ, Holtzman MJ (2009). Macrophage chitinase 1 stratifies chronic obstructive lung disease. Am J Respir Cell Mol Biol, 41(4), 379-84.
  19. Puri V, Scavuzzo M, Guthrie T, Hachem R, Krupnick AS, Kreisel D, Patterson GA, Meyers BF (2009). Lung transplantation and donation after cardiac death: a single center experience. Ann Thorac Surg, 88(5), 1609-14; discussion 1614-5.
  20. Morrell MR, Despotis GJ, Lublin DM, Patterson GA, Trulock EP, Hachem RR (2010). The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant, 29(4), 424-31.
  21. Golocheikine A, Nath DS, Basha HI, Saini D, Phelan D, Aloush A, Trulock EP, Hachem RR, Patterson GA, Ahearn JM, Mohanakumar T (2010). Increased erythrocyte C4D is associated with known alloantibody and autoantibody markers of antibody-mediated rejection in human lung transplant recipients. J Heart Lung Transplant, 29(4), 410-6.
  22. Jain R, Hachem RR, Morrell MR, Trulock EP, Chakinala MM, Yusen RD, Huang HJ, Mohanakumar T, Patterson GA, Walter MJ (2010). Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant, 29(5), 531-7.
  23. Angaswamy N, Saini D, Ramachandran S, Nath DS, Phelan D, Hachem R, Trulock E, Patterson GA, Mohanakumar T (2010). Development of antibodies to human leukocyte antigen precedes development of antibodies to major histocompatibility class I-related chain A and are significantly associated with development of chronic rejection after human lung transplantation. Hum Immunol, 71(6), 560-5.
  24. Hachem RR, Yusen RD, Meyers BF, Aloush AA, Mohanakumar T, Patterson GA, Trulock EP (2010). Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant, 29(9), 973-80.
  25. Saini D, Angaswamy N, Tiriveedhi V, Fukami N, Ramachandran S, Hachem R, Trulock E, Meyers B, Patterson A, Mohanakumar T (2010). Synergistic effect of antibodies to human leukocyte antigens and defensins in pathogenesis of bronchiolitis obliterans syndrome after human lung transplantation. J Heart Lung Transplant, 29(12), 1330-6.
  26. Bharat A, Saini D, Steward N, Hachem R, Trulock EP, Patterson GA, Meyers BF, Mohanakumar T (2010). Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg, 90(4), 1094-101.
  27. Bharat A, Kuo E, Saini D, Steward N, Hachem R, Trulock EP, Patterson GA, Meyers BF, Mohanakumar T (2010). Respiratory virus-induced dysregulation of T-regulatory cells leads to chronic rejection. Ann Thorac Surg, 90(5), 1637-44; discussion 1644.
  28. Saini D, Weber J, Ramachandran S, Phelan D, Tiriveedhi V, Liu M, Steward N, Aloush A, Hachem R, Trulock E, Meyers B, Patterson GA, Mohanakumar T (2011). Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant, 30(6), 624-31.
  29. Tiriveedhi V, Angaswamy N, Brand D, Weber J, Gelman AG, Hachem R, Trulock EP, Meyers B, Patterson G, Mohanakumar T (2012). A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to self-antigen leading to chronic lung allograft rejection. Clin Exp Immunol, 167(1), 158-68.
  30. Weber J, Tiriveedhi V, Takenaka M, Lu W, Hachem R, Trulock E, Patterson GA, Mohanakumar T (2012). Inhibition of renin angiotensin aldosterone system causes abrogation of obliterative airways disease through inhibition of tumor necrosis factor-¿-dependant interleukin-17. J Heart Lung Transplant, 31(4), 419-26.
  31. Hachem RR, Tiriveedhi V, Patterson GA, Aloush A, Trulock EP, Mohanakumar T (2012). Antibodies to K-¿ 1 tubulin and collagen V are associated with chronic rejection after lung transplantation. Am J Transplant, 12(8), 2164-71.
  32. Takenaka M, Subramanian V, Tiriveedhi V, Phelan D, Hachem R, Trulock E, Gelman AE, Patterson GA, Hoshinaga K, Mohanakumar T (2012). Complement activation is not required for obliterative airway disease induced by antibodies to major histocompatibility complex class I: Implications for chronic lung rejection. J Heart Lung Transplant, 31(11), 1214-22.
  33. Mengel M, Campbell P, Gebel H, Randhawa P, Rodriguez ER, Colvin R, Conway J, Hachem R, Halloran PF, Keshavjee S, Nickerson P, Murphey C, O'Leary J, Reeve J, Tinckam K, Reed EF (2013). Precision diagnostics in transplantation: from bench to bedside. Am J Transplant, 13(3), 562-8.
  34. Tiriveedhi V, Gautam B, Sarma NJ, Askar M, Budev M, Aloush A, Hachem R, Trulock E, Myers B, Patterson AG, Mohanakumar T (2013). Pre-transplant antibodies to K¿1 tubulin and collagen-V in lung transplantation: clinical correlations. J Heart Lung Transplant, 32(8), 807-14.
  35. Seccombe J, Mirza F, Hachem R, Gyawali CP (2013). Esophageal motor disease and reflux patterns in patients with advanced pulmonary disease undergoing lung transplant evaluation. Neurogastroenterol Motil, 25(8), 657-63.
  36. Tiriveedhi V, Banan B, Deepti S, Nataraju A, Hachem R, Trulock E, Alexander PG, Thalachallour M (2014). Role of defensins in the pathogenesis of chronic lung allograft rejection. Hum Immunol, 75(4), 370-7.
  37. Baskaran G, Tiriveedhi V, Ramachandran S, Aloush A, Grossman B, Hachem R, Mohanakumar T (2014). Efficacy of extracorporeal photopheresis in clearance of antibodies to donor-specific and lung-specific antigens in lung transplant recipients. J Heart Lung Transplant, 33(9), 950-6.
  38. Ibrahim M, Wang X, Puyo CA, Montecalvo A, Huang HJ, Hachem RR, Andreetti C, Menna C, Chen R, Krupnick AS, Kreisel D, Rendina EA, Gelman AE (2015). Human recombinant apyrase therapy protects against canine pulmonary ischemia-reperfusion injury. J Heart Lung Transplant, 34(2), 247-53.
  39. Bharat A, Cunningham SA, Scott Budinger GR, Kreisel D, DeWet CJ, Gelman AE, Waites K, Crabb D, Xiao L, Bhorade S, Ambalavanan N, Dilling DF, Lowery EM, Astor T, Hachem R, Krupnick AS, DeCamp MM, Ison MG, Patel R (2015). Disseminated Ureaplasma infection as a cause of fatal hyperammonemia in humans. Sci Transl Med, 7(284), 284re3.
  40. Xu Z, Nayak DK, Benshoff N, Hachem R, Gelman AE, Mohanakumar T (2015). De novo-developed antibodies to donor MHC antigens lead to dysregulation of microRNAs and induction of MHC class II. J Immunol, 194(12), 6133-43.
  41. Xu Z, Nayak D, Yang W, Baskaran G, Ramachandran S, Sarma N, Aloush A, Trulock E, Hachem R, Patterson GA, Mohanakumar T (2015). Dysregulated MicroRNA Expression and Chronic Lung Allograft Rejection in Recipients With Antibodies to Donor HLA. Am J Transplant, 15(7), 1933-47.
  42. Xu Z, Ramachandran S, Gunasekaran M, Zhou F, Trulock E, Kreisel D, Hachem R, Mohanakumar T (2015). MicroRNA-144 dysregulates the transforming growth factor-ß signaling cascade and contributes to the development of bronchiolitis obliterans syndrome after human lung transplantation. J Heart Lung Transplant, 34(9), 1154-62.
  43. Bosanquet JP, Witt CA, Bemiss BC, Byers DE, Yusen RD, Patterson AG, Kreisel D, Mohanakumar T, Trulock EP, Hachem RR (2015). The impact of pre-transplant allosensitization on outcomes after lung transplantation. J Heart Lung Transplant, 34(11), 1415-22.
  44. Chen C, Bain KB, Iuppa JA, Yusen RD, Byers DE, Patterson GA, Trulock EP, Hachem RR, Witt CA (2016). Hyperammonemia Syndrome After Lung Transplantation: A Single Center Experience. Transplantation, 100(3), 678-84.
  45. Xu Z, Ramachandran S, Gunasekaran M, Nayak D, Benshoff N, Hachem R, Gelman A, Mohanakumar T (2016). B Cell-Activating Transcription Factor Plays a Critical Role in the Pathogenesis of Anti-Major Histocompatibility Complex-Induced Obliterative Airway Disease. Am J Transplant, 16(4), 1173-82.
  46. Nayak DK, Zhou F, Xu M, Huang J, Tsuji M, Hachem R, Mohanakumar T (2016). Long-Term Persistence of Donor Alveolar Macrophages in Human Lung Transplant Recipients That Influences Donor-Specific Immune Responses. Am J Transplant, 16(8), 2300-11.
  47. Gunasekaran M, Xu Z, Nayak DK, Sharma M, Hachem R, Walia R, Bremner RM, Smith MA, Mohanakumar T (2017). Donor-Derived Exosomes With Lung Self-Antigens in Human Lung Allograft Rejection. Am J Transplant, 17(2), 474-484.
  48. Sofjan AK, Iuppa JA, Bain KB, Deal EN, Witt CA, Hachem RR, Yusen RD (2016). Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients. Ann Pharmacother, 50(10), 824-31.
  49. Xu Z, Sharma M, Gelman A, Hachem R, Mohanakumar T (2017). Significant role for microRNA-21 affecting toll-like receptor pathway in primary graft dysfunction after human lung transplantation. J Heart Lung Transplant, 36(3), 331-339.
  50. Zou J, Duffy B, Slade M, Young AL, Steward N, Hachem R, Mohanakumar T (2017). Rapid detection of donor cell free DNA in lung transplant recipients with rejections using donor-recipient HLA mismatch. Hum Immunol, 78(4), 342-349.
  51. Nayak DK, Zhou F, Xu M, Huang J, Tsuji M, Yu J, Hachem R, Gelman AE, Bremner RM, Smith MA, Mohanakumar T (2017). Zbtb7a induction in alveolar macrophages is implicated in anti-HLA-mediated lung allograft rejection. Sci Transl Med, 9(398).
  52. Aguilar PR, Bemiss BC, Witt C, Byers DE, Kreisel D, Puri V, Meyers B, Patterson GA, Krupnick AS, Yusen RD, Trulock EP, Hachem RR (2017). Impact of Delayed Chest Closure on Surgical Site Infection After Lung Transplantation. Ann Thorac Surg, 104(4), 1208-1214.
  53. Aguilar PR, Carpenter D, Ritter J, Yusen RD, Witt CA, Byers DE, Mohanakumar T, Kreisel D, Trulock EP, Hachem RR (2018). The role of C4d deposition in the diagnosis of antibody-mediated rejection after lung transplantation. Am J Transplant, 18(4), 936-944.
  54. Chang SH, Kreisel D, Marklin GF, Cook L, Hachem R, Kozower BD, Balsara KR, Bell JM, Frederiksen C, Meyers BF, Patterson GA, Puri V (2018). Lung Focused Resuscitation at a Specialized Donor Care Facility Improves Lung Procurement Rates. Ann Thorac Surg, 105(5), 1531-1536.
  55. Brestoff JR, Vessoni AT, Brenner KA, Uy GL, DiPersio JF, Blinder M, Witt CA, Byers DE, Hachem RR, Truclock EP, Early DS, Anadkat MJ, Musiek A, Javidan-Nejad C, Balfe DM, Rosman IS, Liu C, Zhang L, Despotis GJ, Ruzinova MB, Sehn JK, Amarillo I, Heusel JW, Swat W, Kim BS, Wartman LD, Yusen RD, Batista LFZ (2018). Acute graft-versus-host disease following lung transplantation in a patient with a novel TERT mutation. Thorax, 73(5), 489-492.
  56. Gunasekaran M, Sharma M, Hachem R, Bremner R, Smith MA, Mohanakumar T (2018). Circulating Exosomes with Distinct Properties during Chronic Lung Allograft Rejection. J Immunol, 200(8), 2535-2541.
  57. Tambur AR, Campbell P, Claas FH, Feng S, Gebel HM, Jackson AM, Mannon RB, Reed EF, Tinckam K, Askar M, Chandraker A, Chang PP, Colvin M, Demetris AJ, Diamond JM, Dipchand AI, Fairchild RL, Ford ML, Friedewald J, Gill RG, Glotz D, Goldberg H, Hachem R, Knechtle S, Kobashigawa J, Levine DJ, Levitsky J, Mengel M, Milford E, Newell KA, O'Leary JG, Palmer S, Randhawa P, Smith J, Snyder L, Starling RC, Sweet S, Taner T, Taylor CJ, Woodle S, Zeevi A, Nickerson P (2018). Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. Am J Transplant, 18(7), 1604-1614.
  58. Hachem RR, Kamoun M, Budev MM, Askar M, Ahya VN, Lee JC, Levine DJ, Pollack MS, Dhillon GS, Weill D, Schechtman KB, Leard LE, Golden JA, Baxter-Lowe L, Mohanakumar T, Tyan DB, Yusen RD (2018). Human leukocyte antigens antibodies after lung transplantation: Primary results of the HALT study. Am J Transplant, 18(9), 2285-2294.
  59. Balsara KR, Krupnick AS, Bell JM, Khiabani A, Scavuzzo M, Hachem R, Trulock E, Witt C, Byers DE, Yusen R, Meyers B, Kozower B, Patterson GA, Puri V, Kreisel D (2018). A single-center experience of 1500 lung transplant patients. J Thorac Cardiovasc Surg, 156(2), 894-905.e3.
  60. Takahashi T, Gauthier JM, Albertin EK, Damiano RJ Jr, Patterson GA, Bierhals AJ, Pasque MK, Hachem RR, Puri V, Kreisel D (2019). Transplantation of Lungs Procured From a Donor With an Atrioesophageal Fistula. Ann Thorac Surg, 107(2), e121-e122.
  61. Karnes HE, Schindler EI, Morrell M, Hachem RR, Berman K, Vedantham S, Atkinson J, Spitznagel E, Despotis GJ (2019). Factors Associated With Mortality and Response to Extracorporeal Photopheresis in Lung Allograft Recipients With Bronchiolitis Obliterans Syndrome. Transplantation, 103(5), 1036-1042.
  62. Chionis L, Grossman BJ, Hachem R, Commean P, Derfler MC, Vedantham S, Dodds K, Spitznagel E, Atkinson J, Despotis G (2018). The efficacy of extracorporeal photopheresis to arrest bronchiolitis obliterans in lung allograft recipients was compared between two automated photopheresis instruments. Transfusion, 58(12), 2933-2941.
  63. Kulkarni HS, Cherikh WS, Chambers DC, Garcia VC, Hachem RR, Kreisel D, Puri V, Kozower BD, Byers DE, Witt CA, Alexander-Brett J, Aguilar PR, Tague LK, Furuya Y, Patterson GA, Trulock EP 3rd, Yusen RD (2019). Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis. J Heart Lung Transplant, 38(1), 5-16.
  64. Li W, Gauthier JM, Higashikubo R, Hsiao HM, Tanaka S, Vuong L, Ritter JH, Tong AY, Wong BW, Hachem RR, Puri V, Bharat A, Krupnick AS, Hsieh CS, Baldwin WM 3rd, Kelly FL, Palmer SM, Gelman AE, Kreisel D (2019). Bronchus-associated lymphoid tissue-resident Foxp3+ T lymphocytes prevent antibody-mediated lung rejection. J Clin Invest, 129(2), 556-568.
  65. Scozzi D, Ibrahim M, Liao F, Lin X, Hsiao HM, Hachem R, Tague LK, Ricci A, Kulkarni HS, Huang HJ, Sugimoto S, Krupnick AS, Kreisel D, Gelman AE (2019). Mitochondrial damage-associated molecular patterns released by lung transplants are associated with primary graft dysfunction. Am J Transplant, 19(5), 1464-1477.
  66. Gauthier JM, Takahashi T, Bierhals AJ, Brody SL, Hachem RR, Witt CA, Byers DE, Yusen RD, Trulock EP, Aguilar PR, Nava RG, Kozower BD, Meyers BF, Patterson GA, Kreisel D, Puri V (2019). Technical Considerations for Lung Transplantation in Kartagener's Syndrome. Ann Thorac Surg, 107(5), e337-e339.
  67. Puri V, Hachem RR, Frye CC, Harrison MS, Semenkovich TR, Lynch JP, Ridolfi G, Rowe C, Meyers BF, Patterson GA, Kozower BD, Pasque MK, Nava RG, Marklin GF, Brockmeier D, Sweet SC, Chapman WC, Kreisel D (2019). Unintended consequences of changes to lung allocation policy. Am J Transplant, 19(8), 2164-2167.
  68. Tague LK, Witt CA, Byers DE, Yusen RD, Aguilar PR, Kulkarni HS, Bain KB, Fester KA, Puri V, Kreisel D, Mohanakumar T, Trulock EP, Hachem RR (2019). Association between Allosensitization and Waiting List Outcomes among Adult Lung Transplant Candidates in the United States. Ann Am Thorac Soc, 16(7), 846-852.
  69. Gauthier JM, Bierhals AJ, Liu J, Balsara KR, Frederiksen C, Gremminger E, Hachem RR, Witt CA, Trulock EP, Byers DE, Yusen RD, Aguilar PR, Marklin G, Nava RG, Kozower BD, Pasque MK, Meyers BF, Patterson GA, Kreisel D, Puri V (2019). Chest computed tomography imaging improves potential lung donor assessment. J Thorac Cardiovasc Surg, 157(4), 1711-1718.e1.
  70. Halloran KM, Parkes MD, Chang J, Timofte IL, Snell GI, Westall GP, Hachem R, Kreisel D, Trulock E, Roux A, Juvet S, Keshavjee S, Jaksch P, Klepetko W, Halloran PF (2019). Molecular assessment of rejection and injury in lung transplant biopsies. J Heart Lung Transplant, 38(5), 504-513.
  71. Elvington M, Liszewski MK, Liszewski AR, Kulkarni HS, Hachem RR, Mohanakumar T, Kim AHJ, Atkinson JP (2019). Development and Optimization of an ELISA to Quantitate C3(H (2) O) as a Marker of Human Disease. Front Immunol, 10, 703.
  72. Liu Z, Liao F, Scozzi D, Furuya Y, Pugh KN, Hachem R, Chen DL, Cano M, Green JM, Krupnick AS, Kreisel D, Perl AKT, Huang HJ, Brody SL, Gelman AE (2019). An obligatory role for club cells in preventing obliterative bronchiolitis in lung transplants. JCI Insight, 5(9).
  73. January SE, Fester KA, Bain KB, Kulkarni HS, Witt CA, Byers DE, Alexander-Brett J, Trulock EP, Hachem RR (2019). Rabbit antithymocyte globulin for the treatment of chronic lung allograft dysfunction. Clin Transplant, 33(10), e13708.
  74. Tague LK, Scozzi D, Wallendorf M, Gage BF, Krupnick AS, Kreisel D, Byers D, Hachem RR, Gelman AE (2020). Lung transplant outcomes are influenced by severity of neutropenia and granulocyte colony-stimulating factor treatment. Am J Transplant, 20(1), 250-261.
  75. Tague LK, Byers DE, Hachem R, Kreisel D, Krupnick AS, Kulkarni HS, Chen C, Huang HJ, Gelman A (2020). Impact of SLCO1B3 polymorphisms on clinical outcomes in lung allograft recipients receiving mycophenolic acid. Pharmacogenomics J, 20(1), 69-79.
  76. Jacobs MT, Olson M, Ferreira BP, Jin R, Hachem R, Byers D, Witt C, Ghobadi A, DiPersio JF, Pusic I (2020). The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation. Am J Transplant, 20(2), 589-592.
  77. Bansal S, McGilvrey M, Garcia-Mansfield K, Sharma R, Bremner RM, Smith MA, Hachem R, Pirrotte P, Mohanakumar T (2020). Global Proteomics Analysis of Circulating Extracellular Vesicles Isolated from Lung Transplant Recipients. ACS Omega, 5(24), 14360-14369.
  78. Halloran K, Parkes MD, Timofte IL, Snell GI, Westall GP, Hachem R, Kreisel D, Levine D, Juvet S, Keshavjee S, Jaksch P, Klepetko W, Hirji A, Weinkauf J, Halloran PF (2020). Molecular phenotyping of rejection-related changes in mucosal biopsies from lung transplants. Am J Transplant, 20(4), 954-966.
  79. Kulkarni HS, Tsui K, Sunder S, Ganninger A, Tague LK, Witt CA, Byers DE, Trulock EP, Nava R, Puri V, Kreisel D, Mohanakumar T, Gelman AE, Hachem RR (2020). Pseudomonas aeruginosa and acute rejection independently increase the risk of donor-specific antibodies after lung transplantation. Am J Transplant, 20(4), 1028-1038.
  80. Tanaka S, Gauthier JM, Fuchs A, Li W, Tong AY, Harrison MS, Higashikubo R, Terada Y, Hachem RR, Ruiz-Perez D, Ritter JH, Cella M, Colonna M, Turnbull IR, Krupnick AS, Gelman AE, Kreisel D (2020). IL-22 is required for the induction of bronchus-associated lymphoid tissue in tolerant lung allografts. Am J Transplant, 20(5), 1251-1261.
  81. Halloran K, Parkes MD, Timofte I, Snell G, Westall G, Havlin J, Lischke R, Hachem R, Kreisel D, Levine D, Kubisa B, Piotrowska M, Juvet S, Keshavjee S, Jaksch P, Klepetko W, Hirji A, Weinkauf J, Halloran PF (2020). Molecular T-cell'mediated rejection in transbronchial and mucosal lung transplant biopsies is associated with future risk of graft loss. J Heart Lung Transplant, 39(12), 1327-1337.
  82. Sharma M, Gunasekaran M, Ravichandran R, Fisher CE, Limaye AP, Hu C, McDyer J, Kaza V, Bharat A, Tokman S, Omar A, Arjuna A, Walia R, Bremner RM, Smith MA, Hachem RR, Mohanakumar T (2020). Circulating exosomes with lung self-antigens as a biomarker for chronic lung allograft dysfunction: A retrospective analysis. J Heart Lung Transplant, 39(11), 1210-1219.
  83. Gauthier JM, Doyle MBM, Chapman WC, Marklin G, Witt CA, Trulock EP, Byers DE, Hachem RR, Pasque MK, Meyers BF, Patterson GA, Nava RG, Kozower BD, Kreisel D, Chang SH, Puri V (2020). Economic evaluation of the specialized donor care facility for thoracic organ donor management. J Thorac Dis, 12(10), 5709-5717.
  84. Takahashi T, Terada Y, Pasque MK, Itoh A, Nava RG, Puri V, Kreisel D, Patterson AG, Hachem RR (2020). Comparison of outcomes in lung and heart transplant recipients from the same multiorgan donor. Clin Transplant, 34(1), e13768.
  85. Kulkarni HS, Ramphal K, Ma L, Brown M, Oyster M, Speckhart KN, Takahashi T, Byers DE, Porteous MK, Kalman L, Hachem RR, Rushefski M, McPhatter J, Cano M, Kreisel D, Scavuzzo M, Mittler B, Cantu E 3rd, Pilely K, Garred P, Christie JD, Atkinson JP, Gelman AE, Diamond JM (2020). Local complement activation is associated with primary graft dysfunction after lung transplantation. JCI Insight, 5(17).
  86. Nolley E, Fleck J, Kavalieratos D, Dew MA, Dilling D, Colman R, Crespo MM, Goldberg H, Hays S, Hachem R, Lease E, Lee J, Reynolds J, Morrell M, Schenker Y (2020). Lung Transplant Pulmonologists' Views of Specialty Palliative Care for Lung Transplant Recipients. J Palliat Med, 23(5), 619-626.
  87. Yang Z, Gerull WD, Gauthier JM, Meyers BF, Kozower BD, Patterson GA, Nava RG, Hachem RR, Witt CA, Byers DE, Marklin GF, Ridolfi G, Liu J, Kreisel D, Puri V (2020). Shipping Lungs Greater Distances Increases Costs Without Cutting Waitlist Mortality. Ann Thorac Surg, 110(5), 1691-1697.
  88. Tanaka S, Gauthier JM, Terada Y, Takahashi T, Li W, Hashimoto K, Higashikubo R, Hachem RR, Bharat A, Ritter JH, Nava RG, Puri V, Krupnick AS, Gelman AE, Kreisel D (2021). Bacterial products in donor airways prevent the induction of lung transplant tolerance. Am J Transplant, 21(1), 353-361.
  89. Randhawa SK, Yang Z, Morkan DB, Yan Y, Chang SH, Hachem RR, Witt CA, Byers DE, Kulkarni HS, Guillamet RV, Kozower BD, Nava RG, Meyers BF, Patterson GA, Kreisel D, Puri V (2022). One-Year Survival Worse for Lung Retransplants Relative to Primary Lung Transplants. Ann Thorac Surg, 113(4), 1265-1273.
  90. Yang Z, Gerull WD, Shepherd HM, Marklin GF, Takahashi T, Meyers BF, Kozower BD, Patterson GA, Nava RG, Hachem RR, Witt CA, Byers DE, Vazquez Guillamet R, Pasque MK, Yan Y, Kreisel D, Puri V (2021). Different-team procurements: A potential solution for the unintended consequences of change in lung allocation policy. Am J Transplant, 21(9), 3101-3111.
  91. Yang Z, Takahashi T, Gerull WD, Hamilton C, Subramanian MP, Liu J, Meyers BF, Kozower BD, Patterson GA, Nava RG, Hachem RR, Witt CA, Aguilar PR, Pasque MK, Byers DE, Kulkarni HS, Kreisel D, Puri V (2021). Impact of Nighttime Lung Transplantation on Outcomes and Costs. Ann Thorac Surg, 112(1), 206-213.
  92. Terada Y, Gauthier JM, Pasque MK, Takahashi T, Liu J, Nava RG, Hachem RR, Witt CA, Byers DE, Vazquez Guillamet R, Kozower BD, Meyers BF, Aguilar PR, Kulkarni HS, Patterson GA, Kreisel D, Puri V (2021). Clinical Outcomes of Lung Transplants From Donors With Unexpected Pulmonary Embolism. Ann Thorac Surg, 112(2), 387-394.
  93. Itabashi Y, Ravichandran R, Bansal S, Bharat A, Hachem R, Bremner R, Smith M, Mohanakumar T (2021). Decline in Club Cell Secretory Proteins, Exosomes Induction and Immune Responses to Lung Self-antigens, K¿1 Tubulin and Collagen V, Leading to Chronic Rejection After Human Lung Transplantation. Transplantation, 105(6), 1337-1346.
  94. Scozzi D, Cano M, Ma L, Zhou D, Zhu JH, O'Halloran JA, Goss C, Rauseo AM, Liu Z, Sahu SK, Peritore V, Rocco M, Ricci A, Amodeo R, Aimati L, Ibrahim M, Hachem R, Kreisel D, Mudd PA, Kulkarni HS, Gelman AE (2021). Circulating mitochondrial DNA is an early indicator of severe illness and mortality from COVID-19. JCI Insight, 6(4).
  95. Takahashi T, Terada Y, Pasque MK, Liu J, Byers DE, Witt CA, Nava RG, Puri V, Kozower BD, Meyers BF, Kreisel D, Patterson GA, Hachem RR (2021). Clinical Features and Outcomes of Combined Pulmonary Fibrosis and Emphysema After Lung Transplantation. Chest, 160(5), 1743-1750.
  96. Frye CC, Gauthier JM, Bery A, Gerull WD, Morkan DB, Liu J, Shea Harrison M, Terada Y, Van Zanden JE, Marklin GF, Pasque MK, Nava RG, Meyers BF, Patterson AG, Kozower BD, Hachem R, Byers D, Witt C, Kulkarni H, Kreisel D, Puri V (2021). Donor management using a specialized donor care facility is associated with higher organ utilization from drug overdose donors. Clin Transplant, 35(3), e14178.
  97. Terada Y, Harrison MS, Nava RG, Witt CA, Byers DE, Guillamet RV, Meyers BF, Pasque MK, Patterson GA, Kreisel D, Puri V, Hachem RR, Takahashi T (2021). Incidentally Detected Chronic Lymphocytic Leukemia in Hilar Lymph Nodes at the Time of Lung Transplantation: A Case Report. Transplant Proc, 53(8), 2619-2621.
  98. Gerull WD, Yang Z, Kreisel D, Nava R, Meyers BF, Patterson GA, Kozower BD, Hachem RR, Witt C, Byers D, Kulkarni H, Guillamet RV, Marklin G, Puri V (2021). Local versus distant lung donor procurement does not influence short-term clinical outcomes. J Thorac Cardiovasc Surg, 162(4), 1284-1293.e4.
  99. Bansal S, Limaye AP, Lee J, Fleming T, Poulson C, Omar A, Hachem R, Bharat A, Bremner RM, Smith MA, Mohanakumar T (2021). Circulating exosomes induced by respiratory viral infections in lung transplant recipients activate cellular stress, innate immune pathways and epithelial to mesenchymal transition. Transpl Immunol, 69, 101480.
  100. Tague LK, Bedair B, Witt C, Byers DE, Vazquez-Guillamet R, Kulkarni H, Alexander-Brett J, Nava R, Puri V, Kreisel D, Trulock EP, Gelman A, Hachem RR (2021). Lung protective ventilation based on donor size is associated with a lower risk of severe primary graft dysfunction after lung transplantation. J Heart Lung Transplant, 40(10), 1212-1222.
  101. Kapnadak SG, Morrell ED, Wai TH, Goss CH, Shah PD, Merlo CA, Hachem RR, Ramos KJ (2022). Variability in azithromycin practices among lung transplant providers in the International Society for Heart and Lung Transplantation Community. J Heart Lung Transplant, 41(1), 20-23.
  102. Yang Z, Subramanian MP, Yan Y, Meyers BF, Kozower BD, Patterson GA, Nava RG, Hachem RR, Witt CA, Pasque MK, Byers DE, Kulkarni HS, Kreisel D, Itoh A, Puri V (2022). The Impact of Center Volume on Outcomes in Lung Transplantation. Ann Thorac Surg, 113(3), 911-917.
  103. Rahman M, Ravichandran R, Bansal S, Sanborn K, Bowen S, Eschbacher J, Sureshbabu A, Fleming T, Bharat A, Walia R, Hachem R, Bremner RM, Smith MA, Mohanakumar T (2022). Novel role for tumor suppressor gene, liver kinase B1, in epithelial-mesenchymal transition leading to chronic lung allograft dysfunction. Am J Transplant, 22(3), 843-852.
  104. Parkes MD, Halloran K, Hirji A, Pon S, Weinkauf J, Timofte IL, Snell GI, Westall GP, Havlin J, Lischke R, Zajacová A, Hachem R, Kreisel D, Levine D, Kubisa B, Piotrowska M, Juvet S, Keshavjee S, Jaksch P, Klepetko W, Halloran PF (2022). Transcripts associated with chronic lung allograft dysfunction in transbronchial biopsies of lung transplants. Am J Transplant, 22(4), 1054-1072.
  105. Vazquez Guillamet R, Vazquez Guillamet MC, Rjob A, Bierhals A, Bello I, Abularach AJ, Tague L, Wallendorf M, Marklin GF, Witt C, Byers DE, Kreisel D, Nava R, Puri V, Hachem R, Trulock EP (2022). Uncertainty analysis of chest X-ray lung height measurements and size matching for lung transplantation. J Thorac Dis, 14(4), 1042-1051.
  106. Huang HJ, Schechtman K, Askar M, Bernadt C, Mittler B, Dore P, Witt C, Byers D, Vazquez-Guillamet R, Halverson L, Nava R, Puri V, Gelman A, Kreisel D, Hachem RR (2022). A pilot randomized controlled trial of de novo belatacept-based immunosuppression following anti-thymocyte globulin induction in lung transplantation. Am J Transplant, 22(7), 1884-1892.
  107. Yang Z, Takahashi T, Terada Y, Meyers BF, Kozower BD, Patterson GA, Nava RG, Hachem RR, Witt CA, Byers DE, Kulkarni HS, Guillamet RV, Yan Y, Chang SH, Kreisel D, Puri V (2022). A comparison of outcomes after lung transplantation between European and North American centers. J Heart Lung Transplant, 41(12), 1729-1735.
  108. Hachem RR, Patterson GA, Trulock EP (2010). Lung transplantation at Barnes-Jewish Hospital and Washington University in St. Louis. Clin Transpl, 227-34.
  109. Hachem RR (2015). Advancing Lung Transplantation. Clin Transpl, 31, 239-247.
  110. Hachem R (2012). Antibody-Mediated Lung Transplant Rejection. Curr Respir Care Rep, 1(3), 157-161.
  111. Kulkarni HS, Bemiss BC, Hachem RR (2015). Antibody-mediated Rejection in Lung Transplantation. Curr Transplant Rep, 2(4), 316-323.
  112. Thomas L, Hachem R (2016). Bronchiolitis Obliterans Syndrome (BOS) Following Lung Transplant. Am J Respir Crit Care Med, 193(11), P19-20.
  113. Gauthier JM, Hachem RR, Kreisel D (2016). Update on Chronic Lung Allograft Dysfunction. Curr Transplant Rep, 3(3), 185-191.
  114. Witt CA, Hachem RR (2017). Extracorporeal photopheresis for the management of lung allograft rejection. Clin Transplant, 31(10).
  115. Roux A, Levine DJ, Zeevi A, Hachem R, Halloran K, Halloran PF, Gibault L, Taupin JL, Neil DAH, Loupy A, Adam BA, Mengel M, Hwang DM, Calabrese F, Berry G, Pavlisko E (2019). Banff Lung Report: Current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR). American journal of transplantation, 19(1), 21-31.
  116. Gunasekaran M, Bansal S, Ravichandran R, Sharma M, Perincheri S, Rodriguez F, Hachem R, Fisher CE, Limaye AP, Omar A, Smith MA, Bremner RM, Mohanakumar (2020). Respiratory viral infection in lung transplantation induces exosomes that trigger chronic rejection. The Journal of heart and lung transplantation, 39(4), 379-388.
  117. Shepherd HM, Bierhals AJ, Hachem RR, Takahashi T, Pasque MK, Patterson GA, Puri V, Kreisel D, Nava R (2022). Transplantation of Donor Lung With Partial Anomalous Pulmonary Venous Return Using a Carrel Patch. The Annals of thoracic surgery, 114(4), e249-e251.
  118. Terada Y, Puri V, Meyers BF, Kreisel D, Patterson GA, Hachem RR, Takahashi (2022). Lung Transplant for Pulmonary Fibrosis With Dendriform Ossification. The Annals of thoracic surgery, 114(6), e403-e405.
  119. Randhawa SK, Yang Z, Morkan DB, Yan Y, Chang SH, Hachem RR, Witt CA, Byers DE, Kulkarni HS, Guillamet RV, Kozower BD, Nava RG, Meyers BF, Patterson GA, Kreisel D, Puri (2022). One-Year Survival Worse for Lung Retransplants Relative to Primary Lung Transplants. The Annals of thoracic surgery, 113(4), 1265-1273.
  120. Terada Y, Takahashi T, Hachem RR, Liu J, Witt CA, Byers DE, Guillamet RV, Kulkarni HS, Nava RG, Kozower BD, Meyers BF, Pasque MK, Patterson GA, Kreisel D, Puri (2022). Clinical features and outcomes of unplanned single lung transplants. The Journal of thoracic and cardiovascular surgery, 164(6), 1650-1659.e3.
  121. Terada Y, Pasque MK, Witt CA, Nava RG, Kozower BD, Alexander Patterson G, Kreisel D, Puri V, Hachem RR, Takahashi (2026). Trends in primary graft dysfunction and early mortality following lung transplantation: A single center experience. JHLT open, 12, 100488.
  122. Neely M, Mongodin E, Whitson BA, Hachem RR, Anderson MR, Frankel C, Oyster ML, Shaver CM, Morrell ED, Aversa M, Damman AM, Christie J, Palmer SM, Lung Transplant Consortium Investigators and Steering Committe (2026). The NHLBI lung transplant consortium 2025 steering committee report: Strategies to maximize the use of the consortium for advancing lung transplantation. The Journal of heart and lung transplantation, 45(3), 317-323.
  123. Kulkarni HS, Tague LK, Calabrese DR, Liao F, Liu Z, Garnica L, Shankar NR, Wu X, Kulkarni DH, Thapa A, Zhou D, Tao Y, Davis VE, Bernardt CT, Byers DE, Chen C, Huang HJ, Witt CA, Hachem RR, Kreisel D, Atkinson JP, Greenland JR, Gelman A (2025). Impaired complement regulation drives chronic lung allograft dysfunction after lung transplantation. The Journal of clinical investigation, 136(1),
  124. Hachem RR, Gelman A (2025). Game Changer: Extracorporeal Photopheresis for the Prevention of Rejection After Lung Transplantation-A Prospective Randomized Controlled Trial. Transplantation, 109(12), e672-e674.
  125. Ma W, Oh I, Luo Y, Kumar S, Gupta A, Lai AM, Puri V, Kreisel D, Gelman AE, Nava R, Witt CA, Byers DE, Halverson L, Vazquez-Guillamet R, Payne PRO, Sotiras A, Lu H, Niazi K, Gurcan MN, Hachem RR, Michelson A (2025). Developing approaches to incorporate donor-lung computed tomography images into machine learning models to predict severe primary graft dysfunction after lung transplantation. American journal of transplantation, 25(6), 1339-1349.
  126. Liao F, Zhou D, Cano M, Liu Z, Scozzi D, Tague LK, Byers DE, Li W, Sivapackiam J, Sharma V, Krupnick AS, Frank DW, Kreisel D, Kulkarni HS, Hachem RR, Gelman A (2025). Pseudomonas aeruginosa infection induces intragraft lymphocytotoxicity that triggers lung transplant antibody-mediated rejection. Science translational medicine, 17(784), eadp1349.
  127. Tague LK, Anthony H, Salama NN, Hachem RR, Gage BF, Gelman A (2025). An integrated sampling strategy for therapeutic mycophenolic acid monitoring in lung transplant recipients. The Journal of heart and lung transplantation, 44(1), 46-56.
  128. Kulkarni HS, Tague LK, Calabrese DR, Liao F, Liu Z, Garnica L, Shankar N, Wu X, Kulkarni DH, Bernardt C, Byers D, Chen C, Huang HJ, Witt CA, Hachem RR, Kreisel D, Atkinson JP, Greenland JR, Gelman A (2024). Impaired complement regulation drives chronic lung allograft dysfunction after lung transplantation. bioRxiv,

Review

  1. Lawrence KL, Morrell MR, Storch GA, Hachem RR, Trulock EP (2009). Clinical outcomes of solid organ transplant recipients with ehrlichiosis. [Review]. Transpl Infect Dis, 11, (3), 203-10.
  2. Levine DJ, Glanville AR, Aboyoun C, Belperio J, Benden C, Berry GJ, Hachem R, Hayes D Jr, Neil D, Reinsmoen NL, Snyder LD, Sweet S, Tyan D, Verleden G, Westall G, Yusen RD, Zamora M, Zeevi A (2016). Antibody-mediated rejection of the lung: A consensus report of the International Society for Heart and Lung Transplantation. [Review]. J Heart Lung Transplant, 35, (4), 397-406.
  3. Hachem R, Corris P (2018). Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome After Lung Transplantation. [Review]. Transplantation, 102, (7), 1059-1065.
  4. Gauthier JM, Ruiz-Pérez D, Li W, Hachem RR, Puri V, Gelman AE, Kreisel D (2018). Diagnosis, Pathophysiology and Experimental Models of Chronic Lung Allograft Rejection. [Review]. Transplantation, 102, (9), 1459-1466.
  5. Ravichandran R, Bansal S, Rahman M, Sharma M, Liu W, Bharat A, Hachem R, Omar A, Smith MA, Mohanakumar T (2019). The role of donor-derived exosomes in lung allograft rejection. [Review]. Hum Immunol, 80, (8), 588-594.
  6. Shah P, Lowery E, Chaparro C, Visner G, Hempstead SE, Abraham J, Bhakta Z, Carroll M, Christon L, Danziger-Isakov L, Diamond JM, Lease E, Leonard J, Litvin M, Poole R, Vlahos F, Werchan C, Murray MA, Tallarico E, Faro A, Pilewski JM, Hachem RR (2021). Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients. [Review]. J Heart Lung Transplant, 40, (7), 539-556.
  7. Hachem RR, Trulock EP (2004). Bronchiolitis obliterans syndrome: pathogenesis and management. [Review]. Semin Thorac Cardiovasc Surg, 16, (4), 350-5.
  8. Hachem RR, Trulock EP (2008). The new lung allocation system and its impact on waitlist characteristics and post-transplant outcomes. [Review]. Semin Thorac Cardiovasc Surg, 20, (2), 139-42.
  9. Hachem RR (2009). Lung allograft rejection: diagnosis and management. [Review]. Curr Opin Organ Transplant, 14, (5), 477-82.
  10. Hachem RR (2011). Antibodies to human leukocyte antigens in lung transplantation. [Review]. Clin Transpl, 327-32.
  11. Witt CA, Meyers BF, Hachem RR (2012). Pulmonary infections following lung transplantation. [Review]. Thorac Surg Clin, 22, (3), 403-12.
  12. Hachem RR (2018). Immunosuppression: Have We Learnt Anything? [Review]. Semin Respir Crit Care Med, 39, (2), 172-180.
  13. Witt CA, Hachem RR (2013). Immunosuppression: what's standard and what's new? [Review]. Semin Respir Crit Care Med, 34, (3), 405-13.
  14. Halverson LP, Hachem RR (2021). Antibody-Mediated Rejection and Lung Transplantation. [Review]. Semin Respir Crit Care Med, 42, (3), 428-435.
  15. Bery AI, Hachem RR (2020). Antibody-mediated rejection after lung transplantation. [Review]. Ann Transl Med, 8, (6), 411.
  16. Hachem RR (2016). Humoral responses after lung transplantation. [Review]. Curr Opin Organ Transplant, 21, (3), 267-71.
  17. Hachem RR (2017). Acute Rejection and Antibody-Mediated Rejection in Lung Transplantation. [Review]. Clin Chest Med, 38, (4), 667-675.
  18. Hachem RR (2019). The impact of non-HLA antibodies on outcomes after lung transplantation and implications for therapeutic approaches. [Review]. Hum Immunol, 80, (8), 583-587.
  19. Hachem RR (2019). The role of the immune system in lung transplantation: towards improved long-term results. [Review]. J Thorac Dis, 11, (Suppl 14), S1721-S1731.
  20. Hachem RR (2020). Donor-specific antibodies in lung transplantation. [Review]. Curr Opin Organ Transplant, 25, (6), 563-567.
  21. Bedair B, Hachem RR (2021). Management of chronic rejection after lung transplantation. [Review]. J Thorac Dis, 13, (11), 6645-6653.
  22. Levine DJ, Hachem RR (2022). Lung Allograft Rejection. [Review]. Thorac Surg Clin, 32, (2), 221-229.
  23. Bery AI, Belousova N, Hachem RR, Roux A, Kreisel (2025). Chronic Lung Allograft Dysfunction: Clinical Manifestations and Immunologic Mechanisms. Transplantation, 109(3), 454-466.

Editorial

  1. Hachem RR, Reinsmoen NL (2015). What is the definition of a clinically relevant donor HLA-specific antibody (DSA)? Am J Transplant, 15(2), 299-300.
  2. Milross L, Hachem R, Levine D, Glanville AR (2017). Lung autoantibodies: Ready for prime time? J Heart Lung Transplant,
  3. Mulligan MS, Weill D, Davis RD, Christie JD, Farjah F, Singer JP, Hartwig M, Sanchez PG, Kreisel D, Ware LB, Bermudez C, Hachem RR, Weyant MJ, Gries C, Awori Hayanga JW, Griffith BP, Snyder LD, Odim J, Craig JM, Aggarwal NR, Reineck LA (2018). National Heart, Lung, and Blood Institute and American Association for Thoracic Surgery Workshop Report: Identifying collaborative clinical research priorities in lung transplantation. J Thorac Cardiovasc Surg, 156(6), 2355-2365.
  4. Glanville AR, Verleden GM, Todd JL, Benden C, Calabrese F, Gottlieb J, Hachem RR, Levine D, Meloni F, Palmer SM, Roman A, Sato M, Singer LG, Tokman S, Verleden SE, von der Thüsen J, Vos R, Snell G (2019). Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant, 38(5), 483-492.
  5. Verleden GM, Glanville AR, Lease ED, Fisher AJ, Calabrese F, Corris PA, Ensor CR, Gottlieb J, Hachem RR, Lama V, Martinu T, Neil DAH, Singer LG, Snell G, Vos R (2019). Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant, 38(5), 493-503.
  6. Hachem RR (2008). Thrombotic microangiopathy after lung transplantation: a difficult diagnosis. South Med J, 101(7), 683-4.

Letter

  1. Xu Z, Ramachandran S, Gunasekaran M, Zhou F, Trulock E, Kreisel D, Hachem R, Mohanakumar T (2016). MicroRNA-144 is unlikely to play a role in bronchiolitis obliterans syndrome. [Letter to the editor]. J Heart Lung Transplant, 35(4), 543-4.
  2. Bansal S, Tokman S, Fleming T, Maine GN, Sanborn K, Hachem R, Bharat A, Smith MA, Bremner RM, Mohanakumar T (2021). SARS-CoV-2 infection in lung transplant recipients induces circulating exosomes with SARS-CoV-2 spike protein S2. [Letter to the editor]. Clin Transl Med, 11(11), e576.
  3. Oh I, Hachem RR, Michelson A (2026). Reply to Liu, Zehui-Exploring the potential of machine learning in predicting primary graft dysfunction post-lung transplantation. American journal of transplantation, 26(1), 199-201.
  4. Ma W, Hachem RR, Michelson A (2025). Reply to Takefuji, Yoshiyasu - Beyond least absolute shrinkage and selection operator: A comprehensive framework for analyzing complex biological data using nonlinear and nonparametric methods. American journal of transplantation, 25(11), 2475-2476.
  5. Terada Y, Takahashi T, Pasque MK, Kulkarni HS, Vazquez-Guillamet R, Byers DE, Witt CA, Nava RG, Kozower BD, Meyers BF, Patterson GA, Kreisel D, Puri V, Hachem R (2025). Impact of Era on Acute Cellular Rejection After Lung Transplantation. Transplant international, 38, 14534.